UFP Technologies, Inc.
HealthcareNASDAQ:UFPT · NASDAQ Capital Market
-$3.66 today
Vol 0.21M · Avg 0.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
16.1%
avg 11.5%
ROIC
12.6%
avg 9.5%
ROA
10.3%
avg 8.2%
Analysis
ROE is currently the strongest return metric at 16.1% versus its period average of 11.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
R. Jeffrey Bailly | Executive Chairman | $2.27M | — | 64 | $171,200.00 | 2.21% |
Mitchell Caplan Rock | President, CEO & Director | $948,042.00 | — | 58 | $39,115.00 | 0.51% |
Ronald J. Lataille | Chief Financial Officer, Senior Vice President & Treasurer | $870,280.00 | — | 64 | $20,352.00 | 0.26% |
Christopher Litterio | General Counsel, Secretary & Senior Vice President of Human Resources | $638,888.00 | — | 63 | $11,977.00 | 0.15% |
Jason Holt | Senior Vice President | $540,751.00 | — | 52 | $8,978.00 | 0.12% |
Ryan K. Stafford | General Counsel & Senior VP of Human Resources | — | — | 59 | $1,448.00 | 0.02% |
Daniella Mehalik | Vice President of Finance | — | — | 35 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$1.66M
Net Sentiment
$1.66M
Net selling
Most Active
Litterio Christopher P.
10 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $1.66M over the last 12 months. That adds up to net selling of $1.66M. Litterio Christopher P. was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -12.2% | +20.6% (13yr)1 analysts |
| Revenue | N/A | N/A | +2.0% | +13.6% (13yr)1 analysts |
| Net Income | N/A | N/A | -11.3% | +21.3% (13yr)1 analysts |
| EBIT | N/A | N/A | -11.1% | +18.3% (13yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at +2.0% over three years. Forward estimates point to Net Income at +21.3% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.42B
Progyny, Inc.
NASDAQ:PGNY
$2.09B
Select Medical Holdings Corporation
NYSE:SEM
$2.07B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
Alvotech
NASDAQ:ALVO
$1.30B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
CONMED Corporation
NYSE:CNMD
$1.05B
SS Innovations International, Inc.
NASDAQ:SSII
$672.44M
Who manages UFPT?
UFP Technologies, Inc. (UFPT) lists 7 active executives. The top listed executive is R. Jeffrey Bailly, Executive Chairman.
Are UFPT insiders buying or selling?
Recent insider activity shows net selling of $69.67M.
Explore More
Continue the stock analysis
Jump to another research area for this company.